The study found that diabetic patients with breast cancer who received insulin had a 1.65 (95% CI: 1.36–2.02; P-value <0.001) times higher risk of overall mortality compared to those who did not receive insulin (Fig 2). This evidence concerns the gene INS and breast cancer.